Ocular surface and glaucoma, a mutual relationship. Practical suggestions for classification and management

Eur J Ophthalmol. 2023 Aug 30:11206721231199157. doi: 10.1177/11206721231199157. Online ahead of print.ABSTRACTThe chronic use of glaucoma medications could improve the development of an ocular comorbidity, the glaucoma therapy-related ocular surface disease. This could be related to the exposure of the conjunctiva to preservatives, but also active compounds such as prostaglandin analogues may improve the risk of ocular surface inflammation. Inflammation has a negative impact on tolerability and adherence to eyedrops and to the outcome of filtration surgery as well. A stratification of glaucoma patients based not only on visual field progression but also on glaucoma therapy-related ocular surface disease would be desirable for a strategic management. Early diagnosis, individualized treatment, and safe surgical management should be the hallmarks of glaucoma treatment. One of the main issues for the proper and successful management of patients is the right timing, effectiveness and safety for both medical and surgical treatment options leading to a precision medicine in glaucoma disease as the best modern treatment.PMID:37649335 | DOI:10.1177/11206721231199157

Source: European Journal of Ophthalmology - August 31, 2023 Category: Opthalmology Authors: Michele Figus Matteo Sacchi Gemma Caterina Rossi Silvia Babighian Jos é Manuel Benitez Del Castillo Laura de Polo Eugenio Melchionda Chiara Posarelli Source Type: research